Treprostinil Sodium Market Report 2026

Treprostinil Sodium Market Overview

• Treprostinil Sodium market size has reached to $1.25 billion in 2025 • Expected to grow to $1.97 billion in 2030 at a compound annual growth rate (CAGR) of 9.4% • Growth Driver: Rising Prevalence of Pulmonary Diseases Driving Growth In The Market • Market Trend: Advancements In Pulmonary Arterial Hypertension Treatment Formulations For Improved Delivery Methods • North America was the largest region in 2025.

What Is Covered Under Treprostinil Sodium Market?

Treprostinil sodium is a synthetic prostacyclin (PGI₂) analogue that treats pulmonary arterial hypertension (PAH) by improving exercise capacity and symptoms. It promotes vasodilation, inhibits platelet aggregation, and reduces vascular remodeling, lowering pulmonary pressure and enhancing blood flow that helps slow disease progression and improve quality of life. The main product types of treprostinil sodium are injectable, inhalable, and oral. Treprostinil sodium injectable is used to treat pulmonary arterial hypertension (PAH) by improving exercise capacity and reducing symptoms through direct administration via syringe or needle. It is used in various applications such as pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, and others and is distributed through several distribution channels, including hospitals, specialty clinics, online pharmacies, and retail pharmacies.

What Is The Treprostinil Sodium Market Growth Forecast?

The treprostinil sodium market size is expected to see strong growth in the next few years. It will grow to $1.97 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to rising pah prevalence, increasing long-term treatment adoption, expansion of inhalable and oral formulations, growing specialty clinic presence, rising awareness of pah. Major trends in the forecast period include rising use of prostacyclin analog therapies, increasing focus on pulmonary arterial hypertension, expansion of home-based pah treatment, growing adoption of multiple drug delivery routes, increased demand for long-term pah management.

Global Treprostinil Sodium Market Segmentation

1) By Product Type: Injectable, Inhalable, Oral 2) By Applications: Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Other Applications 3) By Distribution Channel: Hospitals, Specialty Clinics, Online Pharmacies, Retail Pharmacies Subsegments: 1) By Injectable: Subcutaneous Injection, Intravenous Infusion 2) By Inhalable: Inhalation Aerosol, Nebulizer Solution 3) By Oral: Extended-Release Tablets, Oral Suspension

What Is The Driver Of The Treprostinil Sodium Market?

The increasing cases of pulmonary diseases are expected to propel the growth of the treprostinil sodium market going forward. Pulmonary diseases are conditions that impact the lungs and respiratory system, disrupting breathing and oxygen flow. The increasing cases of pulmonary disease are due to factors such as air pollution, smoking, environmental toxins, and a growing aging population. Treprostinil sodium is a vasodilator that relaxes lung blood vessels, reduces pressure, improves breathing, and offers flexible treatment for pulmonary diseases. For instance, in June 2025, according to the Office for Health Improvement & Disparities, a UK-based government agency, the rate of emergency hospital admissions for respiratory diseases in England rose by 7% between the financial years ending 2023 and 2024. Therefore, increasing cases of pulmonary diseases are driving the growth of the treprostinil sodium industry.

Key Players In The Global Treprostinil Sodium Market

Major companies operating in the treprostinil sodium market are United Therapeutics Corporation, Liquidia Corporation, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Dr. Reddy's Laboratories Ltd., Mylan Laboratories Limited, Alembic Pharmaceuticals Ltd., Euroapi SA, Cipla Limited, Lupin Limited, Sun Pharmaceutical Industries Ltd., Endo International plc, ChemWerth Inc., LGM Pharma, Simson Pharma Limited, YONSUNG Fine Chemicals Co. Ltd., Nuray Chemicals Private Limited, KPS Chemicals Pharmaceuticals, Farbe Firma Pvt. Ltd., Aurobindo Pharma Limited

Global Treprostinil Sodium Market Trends and Insights

Major companies operating in the treprostinil sodium market are focusing on developing advanced pulmonary arterial hypertension such as pulmonary vasodilator prostacyclin analogy injection to enhance pulmonary hemodynamic control and symptom management in patients with pulmonary arterial hypertension (PAH). Pulmonary vasodilator prostacyclin analog injection refers to a biologically synthesized formulation of prostacyclin or its analogy that is administered intravenously or subcutaneously to dilate pulmonary arteries, reduce pulmonary vascular resistance, and improve blood flow in patients with pulmonary arterial hypertension (PAH). For instance, in April 2023, Dr. Reddy's Laboratories, an India-based pharmaceutical company, announced the launch of Treprostinil Injection in the U.S. market approved by the Food and Drug Administration, a US-based government agency. Treprostinil injection is a therapeutic equivalent generic version of Remodulin (treprostinil) injection that belongs to a group of agents called prostacyclin mimetics used for the treatment of pulmonary arterial hypertension to diminish symptoms associated with exercise. It is supplied in vials of 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL, or 200 mg/20 mL.

What Are Latest Mergers And Acquisitions In The Treprostinil Sodium Market?

In June 2023, Liquidia Corporation, a US-based pharmaceutical corporation, partnered with Pharmosa Biopharm to develop inhaled, sustained-release treprostinil (L606) for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The partnership aims to combine Liquidia’s expertise in pulmonary hypertension with Pharmosa’s experience in inhaled liposomal formulations to transform treatment strategies in regions lacking access to inhaled formulations of treprostinil. Pharmosa Biopharm is a China-based manufacturer of liposomal formulation of treprostinil.

Regional Insights

North America was the largest region in the treprostinil sodium market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Treprostinil Sodium Market?

The treprostinil sodium market consists of sales of nasal spray formulation, buccal or lingual tablet, and nebulized solution. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Treprostinil Sodium Market Report 2026?

The treprostinil sodium market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the treprostinil sodium industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.